Patnaik stressed early diagnosis, rapid treatment, and aggressive surveillance as the backbone of elimination efforts
Health Ministry reviews progress, highlights targeted interventions in high-burden states, and calls for stronger surveillance and stigma reduction to achieve a leprosy-free India
Broadening access for children & patients with inhibitor-complicated hemophilia
The company will present 21 oral and poster presentations spanning investigational and approved therapies
The national platform brought together healthcare professionals, patient advocates, and stakeholders
Vapendavir is an oral, potent, broad-spectrum antiviral active against rhinoviruses and related respiratory enteroviruses
HYMPAVZI is already approved in the US for patients 12 and older with hemophilia A without factor VIII inhibitors or hemophilia B without factor IX inhibitors
The EU approval of DAWNZERA is an important milestone that reflects our ongoing commitment to bring this innovative medicine to people in need across the globe
The guidelines also support reusing tenofovir and abacavir in later regimens for improved outcomes, cost savings, and programmatic efficiency
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
